Melanie Gloria
Chief Operating OfficerMs. Melanie Gloria BSN, is Chief Operating Officer of Immunovant, Inc. from November 2024. She served as Chief Operating Officer of ACELYRIN, Inc. since November 2021 until November 2024. She was Senior Vice President of Development Operations at Horizon Therapeutics Public Limited Company. From June 2018 to November 2021, she was the Senior Vice President Development Operations – ClinOps, Compliance & Standards, Regulatory, Safety & PV at Horizon Therapeutics Public Limited Company. Ms. Gloria served as Senior Vice President of R&D operations at Horizon Therapeutics Public Limited Company since January 24, 2020. After a successful nursing career, she joined the pharmaceutical industry to fulfill her personal mission to have a broader impact on patients' lives. She has experience in the biotechnology industry. Her experience spans across multiple therapeutic areas including cardiovascular, immunology, inflammation, opthalmology, oncology, virology and women’s health. She has a strong operational background having led a variety of research and development functions. She is also an experienced people leader who has led large global diverse teams. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D) functions. She is an experienced people leader who has managed large, diverse teams that achieved global approvals for blockbuster and life-saving therapies at Abbott (NYSE:ABT), AbbVie (NYSE: ABBV) and Horizon Therapeutics (NASDAQ: HZNP). Before joining ACELYRIN, she was senior vice president of development operations at Horizon. From August 2014 through July 2018, Ms. Gloria served as Senior Director of Clinical Program Development at AbbVie Inc. She gets much personal enjoyment from mentoring and supporting others achieve their career aspirations. From November 2009 to August 2014, she was Associate Director of Clinical Program Development for Abbott Laboratories. Most recently at Horizon, she worked with the executive team to build the R&D capabilities and the global team to be a strong growth driver for the company. Throughout her work at Abbott, AbbVie and Horizon she led teams to achieve global approvals of HUMIRA®, Viekera Pak®, Mavyret®, Skyrizi®, Rinvoq®, TEPEZZA® and ORILISSA®. She has been recognized by PharmaVOICE as one of its 100 Most Inspiring People, awarded the Crain's Notable Women in Health Care award and is a Healthcare Business Women Luminary award recipient. Before joining ACELYRIN, she was senior vice president of development operations at Horizon. She received her Bachelor's of Science in Nursing from University of Illinois, Chicago.
Positions
- Company NameImmunovant, Inc.Stock CodeIMVTPositionChief Operating Officer
